Prominent doctors aren’t disclosing their industry ties in medical journal studies. And journals are doing little to enforce their rules
December 11, 2018 / Charles Ornstein
This story was originally published by ProPublica. It was co-published with The New York Times. One is dean of Yale’s medical school. Another is the director of a cancer center in Texas. A third is the next president of the most prominent society of cancer doctors. These leading medical figures are among dozens of doctors who have failed in recent years to report their financial relationships with pharmaceutical and healthcare companies when their studies were published in medical journals, according to a review by ProPublica and The New York Times and data from other recent research. For instance, Howard A. “Skip” Burris III, M.D., the president-elect of the American Society of Clinical Oncology, declared that he had no conflicts of interest in more than 50 journal articles in recent years, including in the prestigious New England Journal of Medicine.